Evidence map›Paper›PMID 30917783›Full record

ArticleBMC cancer2019

Cardiovascular medication use and risks of colon cancer recurrences and additional cancer events: a cohort study.

Erin J A Bowles, Onchee Yu, Rebecca Ziebell, Lu Chen, Denise M Boudreau, Debra P Ritzwoller, Rebecca A Hubbard, Jennifer M Boggs, Andrea N Burnett-Hartman, Andrew Sterrett and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in BMC cancer, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Trial
  3. Review
  4. Hypertension-cancer recurrence crosstalk: implications for survivorship care.Hypertension research : official journal of the Japanese Society of Hypertension · 2026
    Article
  5. Article
  6. Article
  7. Patient and tumour characteristics of screening-age adults diagnosed with screen-detected versus symptomatic colon cancer.Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland · 2022
    Article
  8. Review
  9. Article
  10. Article
  11. Calcium Permeable Channels in Cancer Hallmarks.Frontiers in pharmacology · 2020
    Review
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Erin J A BowlesKaiser Permanente Washington Health Research Institute, 1730 Minor Avenue, Suite 1600, Seattle, WA, 98101, USA. erin.a.bowles@kp.org.ORCID http://orcid.org/0000-0001-6287-7391
Onchee YuKaiser Permanente Washington Health Research Institute, 1730 Minor Avenue, Suite 1600, Seattle, WA, 98101, USA.
Rebecca ZiebellKaiser Permanente Washington Health Research Institute, 1730 Minor Avenue, Suite 1600, Seattle, WA, 98101, USA.
Lu ChenKaiser Permanente Washington Health Research Institute, 1730 Minor Avenue, Suite 1600, Seattle, WA, 98101, USA.
Denise M BoudreauKaiser Permanente Washington Health Research Institute, 1730 Minor Avenue, Suite 1600, Seattle, WA, 98101, USA.
Debra P RitzwollerKaiser Permanente Colorado Institute for Health Research, 2550 S Parker Rd Suite 200, Aurora, Colorado, 80014, USA.
Rebecca A HubbardDepartment of Biostatistics, Epidemiology, and Informatics, Perelman School of Medicine, University of Pennsylvania, 604 Blockley Hall, 423 Guardian Drive, Philadelphia, PA, 19104, USA.
Jennifer M BoggsKaiser Permanente Colorado Institute for Health Research, 2550 S Parker Rd Suite 200, Aurora, Colorado, 80014, USA.
Andrea N Burnett-HartmanKaiser Permanente Colorado Institute for Health Research, 2550 S Parker Rd Suite 200, Aurora, Colorado, 80014, USA.
Andrew SterrettKaiser Permanente Colorado Institute for Health Research, 2550 S Parker Rd Suite 200, Aurora, Colorado, 80014, USA.
Monica FujiiKaiser Permanente Washington Health Research Institute, 1730 Minor Avenue, Suite 1600, Seattle, WA, 98101, USA.
Jessica ChubakKaiser Permanente Washington Health Research Institute, 1730 Minor Avenue, Suite 1600, Seattle, WA, 98101, USA.

Funding

Commonly Used Medications and Risk of Colorectal Cancer RecurrenceR01CA172073 · NCI · KAISER FOUNDATION HEALTH PLAN OF WASHINGTON · PI CHUBAK, JESSICA · 2013 to 2016
$2.1M
Group Health Cancer Research Program Research Specialist AwardR50CA211115 · NCI · KAISER FOUNDATION RESEARCH INSTITUTE · PI BOWLES, ERIN JANELLE AIELLO · 2017 to 2021
$919k
SURVEILLANCE EPIDEMIOLOGY &END RESULTS PROGRAMN01CN067009 · CN · FRED HUTCHINSON CANCER RESEARCH CENTER · PI THOMAS, DAVID B · 1996 to 1997
–
NCI NIH HHS N01 CN067009NCI NIH HHS N01 PC035142NCI NIH HHS R01 CA172073NCI NIH HHS R01CA172073NCI NIH HHS R50 CA211115NCI NIH HHS R50CA211115
6 · The paper itself

Abstract

backgroundCardiovascular medications may be associated with cancer development, but little is known about their association with cancer recurrence. Medications such as statins and antihypertensives may be commonly used among colon cancer survivors, who are, on average, diagnosed in their mid-60s. We described the associations between statins and antihypertensive medications and colon cancer recurrence in a large, population-based study.

methodsWe conducted a cohort study among adults with stage I-IIIA colon cancer diagnosed in 1995-2014 in two Kaiser Permanente regions, Colorado and Washington. Statin and antihypertensive use were obtained from electronic pharmacy dispensing data. People were classified as medication users on the date of their first dispensing after cohort entry, which started 90 days after completing cancer treatment, continuing through the earliest of death, health plan disenrollment, or chart abstraction. We collected outcome information from medical record abstraction and tumor registries on colon cancer recurrences and second primary cancers. Using Cox proportional hazards multivariable models, we estimated hazard ratios (HRs) with 95% confidence intervals (CIs) for colon cancer recurrences and any cancer event (recurrences and new primaries at any anatomic site) comparing medication users to non-users.

resultsAmong 2039 people, 937 (46%) used statins and 1425 (70%) used antihypertensives at any point during a median of 4.9 years of follow-up; 460 people had any additional cancer event, including 152 with a colon cancer recurrence. Statin use was not associated with colon cancer recurrence (HR = 1.09, 95%CI = 0.65-1.85) or any cancer event (HR = 1.12, 95%CI = 0.85-1.47), nor was antihypertensive use associated with recurrence (HR = 0.73, 95%CI = 0.44-1.21) or any cancer event (HR = 0.93, 95%CI = 0.70-1.24).

conclusionsOur results suggest no association between cardiovascular medication use and the risk of recurrence or any additional cancer, and may provide reassurance to colon cancer survivors.

Indexed as

AdultAgedAged, 80 and overAntihypertensive AgentsCancer SurvivorsCardiotoxicityCohort StudiesColonic NeoplasmsElectronic Health RecordsFemaleHumansHydroxymethylglutaryl-CoA Reductase InhibitorsMaleMiddle AgedNeoplasm Recurrence, LocalNeoplasms, Second PrimaryAntihypertensive AgentsHydroxymethylglutaryl-CoA Reductase InhibitorsAntihypertensiveColon cancerRecurrenceStatin

Identifiers

PMID30917783
PMCPMC6437861

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.